Literature DB >> 21073135

Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients.

Kazumi Horiguchi1, Masakazu Toi, Shin-Ichiro Horiguchi, Masahiro Sugimoto, Yasuhiro Naito, Yukiko Hayashi, Takayuki Ueno, Shinji Ohno, Nobuaki Funata, Katsumasa Kuroi, Masaru Tomita, Yoshinobu Eishi.   

Abstract

PURPOSE: We investigated the significance of CD24 and CD44 expression for predicting responses to chemotherapy and prognosis in primary breast cancer patients. PATIENTS AND METHODS: Diagnosis of breast cancer was confirmed by core needle biopsy, and immunohistochemical studies were performed. Preoperatively, patients received anthracycline-containing chemotherapy. Expression of CD44 and CD24 was assessed immunohistochemically and the relationship with chemotherapy response and with prognosis was analyzed.
RESULTS: Between 2001 and 2004, 139 women were enrolled in this study. In the correlation analysis, CD24 expression was negatively associated with pathological response to chemotherapy (p = 0.0003). A machine learning technique with an alternating decision tree (ADTree) showed that four logical rules are involved in predicting the response depending on the combination of CD24, HER2, tumor stage, CD44, progesterone receptor, and patient age. In the survival analysis, patients having CD44 (++) showed a significantly favorable prognosis as compared with others (p = 0.0002). A multivariate analysis showed that CD44 expression had an independent prognostic value (p < .0001).
CONCLUSION: We found a significant correlation between CD44 expression and prognosis and between CD24 expression and response to chemotherapy. CD24 and CD44 expressions would be useful predictive markers, although further studies are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073135

Source DB:  PubMed          Journal:  J Med Dent Sci        ISSN: 1342-8810


  14 in total

1.  CD24 genetic variants contribute to overall survival in patients with gastric cancer.

Authors:  Zhi-Fang Jia; Li-Zhong Wang; Xue-Yuan Cao; Chuan Wang; Dong-Hui Cao; Xing Wu; Li-Li You; Mei-Shan Jin; Yin-Ping Wang; Bao-Sen Zhou; Jing Jiang
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.

Authors:  Agnieszka Adamczyk; Joanna A Niemiec; Aleksandra Ambicka; Anna Mucha-Małecka; Jerzy Mituś; Janusz Ryś
Journal:  J Mol Histol       Date:  2013-07-09       Impact factor: 2.611

3.  Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.

Authors:  Min Hye Jang; Hyun Jong Kang; Ki Seok Jang; Seung Sam Paik; Wan Seop Kim
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

4.  CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

Authors:  T Dan; S M Hewitt; N Ohri; D Ly; B P Soule; S L Smith; K Matsuda; C Council; U Shankavaram; M E Lippman; J B Mitchell; K Camphausen; N L Simone
Journal:  Breast Cancer Res Treat       Date:  2013-11-26       Impact factor: 4.872

5.  Stem cell-related markers in primary breast cancers and associated metastatic lesions.

Authors:  Gulnur Guler; Serdar Balci; Stefan Costinean; Cigdem Himmetoglu Ussakli; Cigdem Irkkan; Dinc Suren; Ebru Sari; Kadri Altundag; Yavuz Ozisik; Susie Jones; Jason Bacher; Charles L Shapiro; Kay Huebner
Journal:  Mod Pathol       Date:  2012-03-02       Impact factor: 7.842

6.  Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model.

Authors:  Masahiro Takada; Masahiro Sugimoto; Yasuhiro Naito; Hyeong-Gon Moon; Wonshik Han; Dong-Young Noh; Masahide Kondo; Katsumasa Kuroi; Hironobu Sasano; Takashi Inamoto; Masaru Tomita; Masakazu Toi
Journal:  BMC Med Inform Decis Mak       Date:  2012-06-13       Impact factor: 2.796

7.  CD24 expression as a marker for predicting clinical outcome in human gliomas.

Authors:  Jianping Deng; Guodong Gao; Liang Wang; Tao Wang; Jia Yu; Zhenwei Zhao
Journal:  J Biomed Biotechnol       Date:  2012-02-28

8.  CD24 and Nanog expression in Stem Cells in Glioblastoma: Correlation with Response to Chemoradiation and Overall Survival

Authors:  Priyanka Soni; Sumaira Qayoom; Nuzhat Husain; Praveen Kumar; Anil Chandra; Bal Krishan Ojha; Rakesh Kumar Gupta
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

9.  CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.

Authors:  Naoki Aomatsu; Masakazu Yashiro; Shinichiro Kashiwagi; Tsutomu Takashima; Tetsuro Ishikawa; Masahiko Ohsawa; Kenichi Wakasa; Kosei Hirakawa
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis.

Authors:  Yangkun Luo; Yan Tan
Journal:  Cancer Cell Int       Date:  2016-06-17       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.